Completed
Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Bimosiamose 5% Cream for the Treatment of Patients With Chronic Plaque Type Psoriasis
What is being tested
Bimosiamose Cream
+ Placebo Cream
Drug
Who is being recruted
Psoriasis+1
+ Skin Diseases
+ Skin and Connective Tissue Diseases
Over 18 Years
+6 Eligibility Criteria
How is the trial designed
Treatment Study
Placebo-ControlledPhase 2
Interventional
Summary
Principal SponsorRevotar Biopharmaceuticals AG
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
The purpose of this study is to determine whether Bimosiamose Cream is safe and effective in the treatment of plaque type psoriasis.
Official TitleMulti-center, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Bimosiamose 5% Cream for the Treatment of Patients With Chronic Plaque Type Psoriasis
Principal SponsorRevotar Biopharmaceuticals AG
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
107 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
PsoriasisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, Papulosquamous
Criteria
3 inclusion criteria required to participate
Clinical diagnosis of plaque type psoriasis PASI score of 5-15
At least 18 years of age
Written informed consent
3 exclusion criteria prevent from participating
Active skin infection
More than 20% Body Surface Area (BSA) affected by psoriasis
Use of certain anti-psoriasis medication or treatments
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
Active ComparatorGroup II
PlaceboStudy Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
Charité Campus Mitte, Klinik für Dermatologie, Venerologie und Allergologie
Berlin, GermanyOpen Charité Campus Mitte, Klinik für Dermatologie, Venerologie und Allergologie in Google MapsCompletedOne Study Center